NasdaqGS - Nasdaq Real Time Price USD

Mersana Therapeutics, Inc. (MRSN)

Compare
2.6300 +0.4300 (+19.55%)
At close: November 13 at 4:00 PM EST
Advanced Chart
Loading Chart for MRSN
DELL
  • Previous Close 2.2000
  • Open 2.6500
  • Bid 2.5800 x 200
  • Ask 2.6600 x 100
  • Day's Range 2.5200 - 2.8260
  • 52 Week Range 1.2200 - 6.2800
  • Volume 2,878,645
  • Avg. Volume 1,029,801
  • Market Cap (intraday) 322.635M
  • Beta (5Y Monthly) 1.48
  • PE Ratio (TTM) --
  • EPS (TTM) -0.8500
  • Earnings Date Nov 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.50

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

www.mersana.com

123

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Mersana Therapeutics, Inc.

Recent News: MRSN

View More
View More

Performance Overview: MRSN

Trailing total returns as of 11/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MRSN
13.36%
S&P 500
25.48%

1-Year Return

MRSN
117.36%
S&P 500
35.56%

3-Year Return

MRSN
71.23%
S&P 500
27.81%

5-Year Return

MRSN
14.35%
S&P 500
93.59%

Compare To: MRSN

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

MRSN
Mersana Therapeutics, Inc.
2.6300
+19.55%
Mkt Cap 322.635M
Industry Biotechnology
MGNX
MacroGenics, Inc.
3.7700
-8.05%
Mkt Cap 236.618M
Industry Biotechnology
CTMX
CytomX Therapeutics, Inc.
1.0100
-2.88%
Mkt Cap 79.041M
Industry Biotechnology
STRO
Sutro Biopharma, Inc.
3.9600
-2.94%
Mkt Cap 324.576M
Industry Biotechnology
XNCR
Xencor, Inc.
23.61
-0.42%
Mkt Cap 1.652B
Industry Biotechnology
ZNTL
Zentalis Pharmaceuticals, Inc.
3.9200
+5.66%
Mkt Cap 279.36M
Industry Biotechnology
KPTI
Karyopharm Therapeutics Inc.
0.8662
-3.52%
Mkt Cap 108.548M
Industry Biotechnology
VOR
Vor Biopharma Inc.
0.9588
-3.12%
Mkt Cap 65.844M
Industry Biotechnology
RAPT
RAPT Therapeutics, Inc.
1.5700
-9.77%
Mkt Cap 54.885M
Industry Biotechnology
KZR
Kezar Life Sciences, Inc.
7.54
+0.67%
Mkt Cap 55.014M
Industry Biotechnology
LYEL
Lyell Immunopharma, Inc.
1.1000
-5.58%
Mkt Cap 307.143M
Industry Biotechnology

Statistics: MRSN

View More

Valuation Measures

Annual
As of 11/13/2024

  • Market Cap

    322.64M

  • Enterprise Value

    192.20M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.66

  • Price/Book (mrq)

    38.29

  • Enterprise Value/Revenue

    6.42

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.30%

  • Return on Equity (ttm)

    -213.33%

  • Revenue (ttm)

    29.94M

  • Net Income Avi to Common (ttm)

    -104.77M

  • Diluted EPS (ttm)

    -0.8500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    162.74M

  • Total Debt/Equity (mrq)

    390.80%

  • Levered Free Cash Flow (ttm)

    -66.51M

View More

Research Analysis: MRSN

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 12.6M
Earnings -11.5M
Q4'23
Q1'24
Q2'24
Q3'24
-20M
-10M
0
10M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

3.00
6.50 Average
2.6300 Current
9.00 High
 
View More

Company Insights: MRSN

People Also Watch

CTMX CytomX Therapeutics, Inc.
1.0100
-2.88%
 
MGNX MacroGenics, Inc.
3.7700
-8.05%
 
STRO Sutro Biopharma, Inc.
3.9600
-2.94%
 
KURA Kura Oncology, Inc.
17.75
-4.42%
 
REPL Replimune Group, Inc.
11.69
-4.10%
 
KZR Kezar Life Sciences, Inc.
7.54
+0.67%
 
PTGX Protagonist Therapeutics, Inc.
42.67
-1.16%
 
SNDX Syndax Pharmaceuticals, Inc.
16.63
+2.59%
 
YMAB Y-mAbs Therapeutics, Inc.
13.18
0.00%
 
SRRK Scholar Rock Holding Corporation
27.38
+2.70%
 
RYTM Rhythm Pharmaceuticals, Inc.
60.07
-6.23%
 
STOK Stoke Therapeutics, Inc.
13.90
+2.06%
 
RCUS Arcus Biosciences, Inc.
16.43
-2.03%
 
ANAB AnaptysBio, Inc.
20.75
-3.49%
 
IDYA IDEAYA Biosciences, Inc.
30.49
-1.58%
 
AKRO Akero Therapeutics, Inc.
30.97
-4.35%